88655-07-6

Upstream product

• 55-81-2 4-Methoxyphenethylamine 
• 292638-85-8 acrylic acid methyl ester 

Downstream Products

• 88655-27-0 1-[2-(4-Methoxy-phenyl)-ethyl]-2-thioxo-tetrahydro-pyrimidin-4-one 
• 88655-17-8 1-[2-(4-Methoxy-phenyl)-ethyl]-dihydro-pyrimidine-2,4-dione 
• 289637-67-8 methyl 3-[(4-methoxyphenethyl)-(4-cyanobenzenesulfonyl)-amino]-propionate 
• 289638-78-4 FG 1891 
• 1415586-30-9 C₂₆H₂₇F₃N₄O₆S 
• 551929-72-7 3-{[4-(3,3-dibenzylureido)benzenesulfonyl]-[2-(4-methoxyphenyl)ethyl]amino}-N-hydroxypropionamide 
• 289638-60-4 FG 1895 
• 289638-61-5 FG 1896 
• 289638-54-6 FG 1730 

Relevant academic research and scientific papers

Design and synthesis of procollagen C-proteinase inhibitors

Non-peptidic inhibitors of procollagen C-proteinase (PCP) were designed from substrate leads. Compounds were optimized for potency and selectivity, with N-substituted aryl sulfonamide hydroxamates having the best combination of these properties. Compounds

N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production

The present invention relates to a novel class of organic molecules capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of fibrotic disorders

Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa

Several classes of peptidomimetics of the efflux pump inhibitor D-ornithine-D-homophenylalanine-3-aminoquinoline (MC-02,595) have been prepared and evaluated for their ability to potentiate the activity of the fluoroquinolone levofloxacin in Pseudomonas a